Utilization trends for GLP1s (glucagon-like peptides, used to treat diabetes and sometimes obesity) will continue to increase in 2024, adding cost to the system and pressure on payers and employers to cover treatments.
Lasting Effects of GLP1s was a healthcare industry trend in our 2024 March Healthcare Classic. Explore this year’s interactive bracket to see the most impactful healthcare trends face off.